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staging Carcinoma of the Prostate 
Joseph C. Cerny, MD* 
For patients with carcinoma of the prostate, staging is cmcial in determining the severity of the disease, its prognosis, and 
how therapy will be guided. The staging categories, staging 
methods and their applications, and the impact of staging on 
therapeutic results and patient management are discussed 
herein. 
Staging Systems 
The most widely used staging nomenclature is the modified 
Whitmore-Jewett system. Most urologists are familiar with this 
system as it is commonly used in clinical situations and has been 
widely discussed in the literature. Stage A represents the inci-
dental finding of carcinoma, usually discovered after trans-
urethral prostatectomy for obstmction. In stage A-l less than 5% 
of the resected tissue is neoplastic and well differentiated, 
whereas in stage A-2 greater than 5% of the tissue is neoplastic 
and/or poorly differentiated. In stage B the lesion is palpable 
and confined to the prostate gland. In stage B-l the nodule is 
confined to less than one lobe and is surrounded by normal pros-
tate tissue, whereas in stage B-2 the palpable nodule is more ex-
tensive, usually involving one ormore lobes, though still within 
the confines of the prostate gland. In stage C the carcinoma ex-
tends beyond the prostate, but without distant metastases. Mini-
mal extracapsular extension is seen in stage C-1, and stage C-2 
consists of bulky tumor with bladder outiet and/or ureteral 
obstmction. Distant metastases characterize stage D. In stage 
D-1 pelvic lymph node metastases are found by surgery or by 
needle biopsy. In stage D-2 distant metastatic disease is evident, 
usually in the bones, whereas stage D-3 indicates a relapse fol-
lowing endocrine therapy. 
The tumor, node, metastasis (TNM) staging system, which is 
preferred in many parts of the world including Europe, has the ad-
vantage of describing the status of the local disease as well as the 
extent of the nodal involvement and distant disease. While most 
urologists and oncologists prefer the modified Whitmore-Jewett 
system to the TNM system, some combination of these two sys-
tems will ultimately provide a universal staging system (1). 
Serum Studies 
Following the histologic diagnosis of prostatic adenocar-
cinoma, semm studies are necessary for accurate staging of the 
disease. These include prostatic acid phosphatase (PAP), al-
kaline phosphatase, and prostate specific antigen (PSA). 
While semm studies are essential to the staging process, idio-
syncracies of each of these biochemical parameters have limited 
specificity in describing the precise status of the neoplasm. In-
terpretation of acid phosphatase levels in individual patients is 
difficult because results may be normal both in patients with 
cancer confined to the prostate gland and in up to 30% of patients 
with metastatic disease. Conversely, some patients with benign 
prostatic hypertrophy (BPH), as well as those with nonprostatic 
disease such as osteitis deformans (Paget disease), multiple my-
eloma, or blood dyscrasias may have elevated semm acid phos-
phatase. Furthermore, patients who have had recent urethral in-
strumentation or palpation of a benign prostate gland may 
exhibit transient (24 to 48 hr) elevation of PAP. Compared to en-
zymatic assays for measuring PAP, radioimmunoassays and 
counterimmunoelectrophoresis are more sensitive, but the fre-
quent occurrence of false-positive results makes these tests un-
acceptable for screening purposes. 
Elevation of alkaline phosphatase in patients with carcinoma 
ofthe prostate is associated with metabolic bone repair in an area 
of osseous metastasis as well as with liver disease. The semm 
alkaline phosphatase level is particularly useful in documenting 
response to endocrine therapy in patients with skeletal metasta-
ses (2). 
PSA has recently been evaluated as a marker in BPH and in 
localized and disseminated carcinoma of the prostate. Thus, in 
patients with BPH, PSA levels greater than 4 |xg/L (normal = 0 
to 4 |i.g/L) were noted in 20% of patients and levels greater than 
10 |jLg/L were noted in another 3% to 5% of patients. In localized 
carcinoma of the prostate, PSA levels greater than 4 ji-g/L were 
noted in 60% of patients and levels greater than 10 p-g/L were 
noted in 30% to 50% of patients. In active stage D-2 disease, 
PSA levels greater than 4 p-g/L occurred in 98% of patients. 
Comparison of PAP levels in control patients and in those 
with BPH and carcinoma of the prostate stages A through D 
demonstrates that while not much difference exists between 
BPH and stages A and B prostate carcinoma, PAP levels pro-
gressively increase with advancing stages of carcinoma of the 
prostate. Thus, as noted by Ercole et al (3), PAP is elevated in 
10% of patients with stage A, 24% with stage B, 53% with stage 
C, and 92% with stage D disease. Since significant elevations of 
PAP are found in patients with BPH, PAP is not recommended 
for screening but is a useful marker in monitoring patients with a 
known diagnosis of carcinoma of the prostate. 
Comparison of PAP and PSA in carcinoma of the prostate is of 
interest. In a recent study, PAP and PSA were studied in 136 con-
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secutive patients. The disease was localized in 43 patients and 
had metastasized in 94 patients. The overall sensitivity of PSA 
was 89% whereas PAP was 62%. In localized disease only, sen-
sitivity of PSA was 79% and PAP 41%, while in metastatic dis-
ease PSA was 93% sensitive, PAP 72%, and alkaline phos-
phatase 63%. In another study correlating semm PAP levels and 
final pathologic stage as determined on the radical prostatec-
tomy specimen, patients with capsular penetration had the high-
est percentage of elevated levels of PAP, whereas those with 
seminal vesicle involvement had intermediate elevation, and 
patients with node involvement had the lowest correlation (4). 
Understaging 
Understaging occurs in a significant percentage of patients 
with prostate carcinoma, with the clinical stage typically lower 
than the true pathologic stage. In patients presumed to have 
stage A- l , B-l , and B-2 carcinoma, the frequency of both micro-
scopic and macroscopic local tumor invasion in radical pros-
tatectomy specimens was from 15% to 30%. In clinical stages 
A-2, B-l , and B-2, significant percentages of capsular invasion, 
seminal vesicle invasion, and lymph node metastasis were 
found. According to Epstein et al (5), in padents with presumed 
A-l disease, based on transurethral prostatectomy, subsequent 
radical prostatectomy revealed an 86% incidence of significant 
residual disease and in many cases large volume residual dis-
ease. Interestingly, no correlation existed between the amount of 
neoplasm found on the transurethral specimen, or its grade, and 
subsequent volume of tumor in the radical specimen. 
Radiologic Studies 
Radiologic studies used in the staging of prostate carcinoma 
include chest x-ray, bone scans and skeletal x-rays, intravenous 
pyelograms, lymphangiography, prostatic ultrasound, com-
puted tomography (CT), and magnetic resonance imaging 
(MRI). Pulmonary metastases are usually depicted by a streak-
ing rather than a nodular appearance. Rib metastases may also 
be seen. Intravenous pyelograms may show bladder floor eleva-
tion or in more advanced cases ureteral obstmction or deviation. 
Many bone scans show some degree of abnormality. In prostate 
cancer bony involvement is axial and occurs as well in the pel-
vis. However, metastases must be differentiated from prior frac-
tures and arthritis. When in doubt, a bone biopsy is necessary. 
Skeletal x-rays in the area of the bone scan abnormality will de-
pict typical changes characteristic of blastic prostate cancer me-
tastases. Lymphangiography is tedious to perform and has been 
replaced by CT and MRI studies for patients with prostate car-
cinoma. Lymph node assessment, which is particularly impor-
tant in the preoperative staging of patients with prostate car-
cinoma, is done by either CT-guided needle biopsy or by pelvic 
lymphadenectomy. 
Prostatic ultrasound is useful in demonstrating capsular in-
volvement, periprostatic extension, and seminal vesicle inva-
sion (6). These areas can be selectively sampled in patients in 
whom stage C disease is suspected. Since most patients with 
stage C disease are candidates for radiation therapy or hormonal 
therapy and not radical prostatectomy, an ultrasound-guided bi-
opsy of this area is imperative. Similarly, the pelvic CT scan is 
useful in showing the prostatic capsule and the possibility of dis-
mpdon. MRI has also been useful in staging involvement ofthe 
bladder neck and seminal vesicles (7). At Henry Ford Hospital 
we prefer to use the ultrasound-guided perineal needle biopsy, 
although transrectal ultrasound-guided biopsies are also per-
formed. A study of 27 patients with biopsy-proven prostatic car-
cinoma compared the sensitivity of MRI and ultrasound to each 
other and to CT in staging the disease. Sonography was superior 
to MRI for detection of intraglandular carcinoma and capsular 
dismption, whereas MRI was superior to both sonography and 
CT for evaluating seminal vesicle invasion and was slightly bet-
ter than CT for detecting lymphadenopathy (8). 
Conclusions 
Errors are inherent in all staging procedures. Once staging 
data are obtained and assembled, the urologist must discuss with 
the patient and his family the pros and cons of extemal radiation 
therapy and radical prostatectomy for the treatment of stage A-1, 
A-2, B-l, and B-2 disease. Both modalities have been consid-
ered equal in the treatment of prostate carcinoma. However, 
based on results obtained with the recently introduced nerve-
sparing technique, 1 prefer that young and otherwise healthy pa-
tients with localized, early stage prostatic carcinoma be treated 
by radical prostatectomy rather than with external radiation 
therapy. 
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